Billionaire Value Investor Michael Price Adds Specialty Retailer and a REIT to Its 13F Portfolio

Page 3 of 3

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)

– Shares Held By MFP Investors (as of December 31): 696,500

– Value of The Holding (as of December 31): $25.25 Million

After having increased its stake in Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) by 6% during the third quarter, MFP Investors again boosted its holding in the beleaguered drug company by 48% during the fourth quarter. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) lost almost 45% of its market capitalization last year amid several troubles including ballooning of debt after purchasing Allergan’s generic drug business for over $40 billion, losing patent exclusivity of its bestselling drug Copaxone and allegations that it was part of a price-fixing nexus among generic drug manufacturers. Although a lot of analysts and investors have given up hope on the Israeli drug manufacturer, there are a sizeable number of contrarians who think that the stock has bottomed out now.

Follow Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

BMC Stock Holdings Inc (NASDAQ:BMCH)

– Shares Held By MFP Investors (as of December 31): 3.42 Million

– Value of The Holding (as of December 31): $66.7 Million

Although MFP Investor didn’t make any changes to its stake in BMC Stock Holdings Inc (NASDAQ:BMCH) during the fourth quarter, the company still jumped a spot and became the fund’s top equity holding at the end of December owing to a 10% rise in its stock during the October-December period. The Raleigh, NC-based lumber and building materials distributor got listed on NASDAQ in August 10, 2013 at a price of $17 per share. Since then its stock has appreciated by around 17.5%. Earlier this month, analysts at Barclays PLC initiated coverage on the stock with an ‘Overweight’ rating and $22 price target, suggesting a potential upside of 10%.

Follow Bmc Stock Holdings Inc. (NASDAQ:BMCH)

Disclosure: None

Page 3 of 3